Clinical Trial Update: GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial of GEMOX with donafenib and tislelizumab in biliary tract carcinoma is in Phase 1/2 with unknown results to date.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Carcinoma

Drugs mentioned

• Donafenib (donafenib)
• GEMOX (gemcitabine + oxaliplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Biliary Tract Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN